Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLB-002 in Relapsed or Refractory Non-Hodgkin Lymphomas
NCT06219356Phase 1Recruiting
- Sponsor
- GluBio Therapeutics
- Start
- Jan 2024
- Primary completion
- Jan 2026
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment), Molecular Glues
- Countries
- 1
01
Overview
Phase 1, open-label trial of GLB-002 in non-Hodgkin lymphoma (NHL) (4 arms), sponsored by GluBio Therapeutics. Primary endpoints: Dose-limiting Toxicity, Maximum Tolerated Dose up to 2 years and 8 more. Started Jan 2024; status: recruiting.
02
Drugs
GLB-002
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT06219356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06219356.